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Stability and membrane localization of Transforming growth factor-β (TGF-β) type 
I receptor (TβRI) is essential for controlling TGF-β signaling1, 2. TβRI is targeted for 
ubiquitination-mediated degradation by Smad7/Smurf2 complex. However, it is 
unclear whether polyubiquitin modified TβRI can be reversed. Here we performed 
a genome-wide gain of function screen and identified ubiquitin-specific protease 
(USP) 4 as a strong inducer of TGF-β signaling. Putative oncogenic USP4 was found 
to interact with TβRI as deubiquitinating enzyme thus maintains TβR1 levels at the 
plasma membrane. Depletion of USP4 mitigates TGF-β-induced breast cancer cell 
migration, epithelial to mesenchymal transition and metastasis. Importantly, 
Akt/Protein kinase B (PKB) 3, 4, which has been associated with poor prognosis in 
breast cancer 5, 6, associates with and phosphorylates USP4. Akt mediated 
phosphorylation relocates USP4 to cytoplasm and membrane and is required for 
maintaining its protein stability. Moreover, Akt-induced breast cancer cell 
migration was inhibited by USP4 depletion and TβRI kinase inhibition. Our results 
identified USP4 as an important determinant for crosstalk between TGF-β and Akt, 
which provides new opportunities for cancer treatment. 
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TGF-β is of critical importance for embryogenesis and tissue homeostasis of 
multicellular organisms. Perturbations in its signaling pathways have been linked to a 
diverse set of human diseases, including cancer7, 8. The TGF-β activated serine/threonine 
kinase receptor complex propagates the signal by phosphorylating receptor regulated (R)-
Smads, i.e Smad2 and Smad3. Activated R-Smads form hetero-oligomers with Smad4 
that accumulate into the nucleus to regulate a large number of target genes 1, 2, 7, 8. Besides 
Smad pathway, also non-Smad signaling pathways are initiated that include the 
phosphatidylinositol-3-kinase (PI3K)/AKT pathway9-11. These non-canonical pathways 
are also activated by growth factors that signal via tyrosine kinase receptors to mediate 
cell proliferation, survival and migration. During cancer progression, TGF-β frequently 
switches from tumor suppressor to tumor promoter. Oncogenic signals may blunt TGF-β-
induced growth arrest and apoptosis, while enhance TGF-β-induced pro-invasive and 
pro-metastatic responses, and this may involve a change in balance between canonical 
and non-Smad signaling12-14  
TGF-β signaling is intricately controlled by multiple positive and negative 
regulators. Smad7 is a potent negative regulator of TGF-β signaling by recruiting Smurf 
E3 ubiquitin ligases to the activated TβRI and targeting this receptor for degradation 15, 16. 
Whether this process can be reversed via action of specific deubiquitinating enzymes 
(DUBs)17-20 is unknown. To identify novel critical components of TGF-β signaling, we 
performed a gain of function screen overexpressing 27,000 genes using a TGF-β-induced 
Smad3/4 driven transcriptional reporter as read out.  Multiple DUBs, including USP4, -
11 -19 and -15  potently activated the TGF-β-induced signal (Fig. 1a), of which USP15 
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was just known as a deubiquitinating enzyme for R-Smad 21.  An independent screen with 
69 Flag-tagged DUB cDNAs (with comparable expression levels of each DUB) 
confirmed the same USPs as selective activators of TGF-β, but not IL1β/NFκ-induced 
transcriptional response (Supplementary Fig. S1a and S1b and data not shown). In 
contrast to USP4 wild-type, the USP4 CS mutant (carrying a point mutation in one of the 
key cysteines of the catalytic domain) did not potentiate TGF-β signaling (Fig.1b). This 
suggests that the DUB activity is needed for this response. Knock-down with two 
independent shRNAs that selectively target USP4, demonstrated that endogenous USP4 
expression is required for maximal TGF-β-induced transcriptional response in HEK293T 
cells (Fig. 1c). These results were consolidated in other cell types. Ectopic expression of 
wild-type USP4, but not the CS mutant increased both magnitude and duration of TGF-β-
induced Smad2/Smad4 complex formation in MCF10A-Ras (M2) breast cancer cells 
(Fig. 1d). Depletion of endogenous USP4 decreased this effect in MDA-MB-231 breast 
cancer cells (Fig.1e). Moreover, both duration and intensity of TGF-β-induced Smad2 
phosphorylation and downstream target gene expression were impaired in USP-/- cells 
compared to USP+/+ mouse embryonic fibroblasts (MEFs) (Fig. 1f and 1g). To investigate 
the role of USP4 in vivo we depleted USP4 in zebrafish using morpholino 
oligonucleotides (with depleting effects confirmed, data not shown), and observed a 
serious epiboly defect before the formation of zebrafish tail bud is completed (data not 
show). Usp4 morphant embryos showed severe inhibition in expression of TGF-β targets 
goosecoid (gsc) and notail (ntl) (Fig. 1h), and these genes were elevated in embryos 
injected with usp4 mRNA as measured by in situ hybridization (Fig. 1h).  Consistently, 
qPCR results of gsc, ntl, sox17 and sox32 confirmed the effects of USP4 expression on 
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target gene expression in vivo (Fig. 1i), Taken together, these results indicate that USP4 
is a critical regulator of TGF-β signaling in mammalian cells and zebrafish embryos. 
The results above indicate that USP4 acts as a deubiquitylase in the TGF-β 
pathway, and operates upstream of R-Smad activation. This prompted us to test whether 
USP4 targets TGF-β receptor function. We first analyzed whether USP4 and TβRІ can 
physically interact with each other. Upon overexpression, USP4 binds TβRІ 
(Supplementary Fig S2a). Interestingly, the association with (endogenous) USP4 was 
more efficient upon TβRI activation (Supplementary Fig S2a and S2b). Moreover, USP4 
antibodies were able to co-immunoprecipate 125I-TGF-β affinity labeled endogenous 
receptors, which validates the interaction between USP4 and TGF-β receptor (Fig. 2a). 
Furthermore, endogenous USP4 was found to interact with TβRI in a TGF-β-induced 
manner in HeLa cells (Fig. 2b).  Therefore, USP4 binds TβRІ at physiological conditions.   
We eluted TβRІ from a USP4 complex. We found wild-type USP4 associated 
TβRІ was not ubiquitinated while USP4 cs mutant associated TβRІ was highly 
ubiquitinated (Fig. S2c). We thus asked if USP4 serves as a DUB for TβRІ. Firstly, Flag-
tagged caTβRІ proteins were affinity purified and their ubiquitination pattern was 
visualized by immunoblotting for HA–ubiquitin; polyubiquitination appeared as a major 
modification of TβRІ. Overexpression of wild-type USP4, but not of a catalytically 
inactive USP4 mutant, inhibited TβRІ Lysine 48 polyubiquitination in the absence or 
presence of proteasome inhibitor MG132 (Fig. 1c). TGF-β receptor signaling induces 
Smad7 expression, which subsequently targets TβRІ degradation by recruiting E3 ligase 
Smurf2 15, 16. USP4 opposed Smad7/Smurf2-induced TβRІ ubiquitination 
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(Supplementary Fig. 2d), and blocked TGF-β-induced TβRІ ubiquitination at the 
endogenous level (Fig. 2d). Conversely, USP4 depletion enhanced TGF-β-induced TβRІ 
Lysine 48 polyubiquitination (Fig.2e). The modification of TβRІ by Lysine-48 linked 
polyubiquitination has been reported to promote its internalization and degradation22. We 
therefore tested whether USP4 misexpression can regulate TβRІ levels at the 
plasmembrane, the location where signaling is initiated 22. When coexpressed with wild-
type USP4, but not with the catalytically inactive mutant, biotin-labeled cell surface TβRI 
receptor displayed a prolonged half-life (Fig. 2f). In line with this finding, USP4 
depletion in MDA-MB-231 cells led to lower cell surface TβRІ expression and 
accelerated degradation (Fig 2g). Moreover, when compared to USP4+/+ MEFs, USP4-/- 
MEFs showed lower expression level and shorter half-life of TβRI (Fig.2h). These 
findings indicate that USP4 is a DUB for TβRI and contributes to increased stability of 
TβRI at the plasmamembrane. 
USP4 is highly expressed in different cancers, including breast cancer 23. TGF-β 
stimulates epithelial to mesenchymal transition (EMT), cell migration, invasion and 
metastasis of breast cancer7, 24.  Typical EMT changes are: upregulation of N-cadherin, 
fibronectin, smooth muscle actin and vimentin and downregulation of E-cadherin 25. 
Upon depletion of USP4, TGF-β-induced changes in EMT marker expression were 
attenuated (Fig. 3a). Conversely, ectopic expression of USP4, but not its CS inactive 
mutant, potentiated these TGF-β-induced changes in expression (Fig.3b).  Consistent 
with these results, USP4 knockdown attenuated TGF-β-induced migration of MDA-MB-
231 cells (Fig. 3c). These results suggest that USP4 regulates TGF-β-induced EMT and 
migration of breast cancer cells in vitro.  
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We next examined the effect of USP4 misexpression in breast cancer cells in vivo 
by using zebrafish embryo xenograft model where mammalian tumor cells are injected 
into the zebrafish embryonic blood circulation (for technical details, see materials and 
methods) (Fig. 3d). MCF10A-Ras cells stably infected with wild-type USP4, inactive 
USP4 CS mutant or an empty vector control were injected into the blood circulation of 
the zebrafish embryo.  Invasion and micrometastasis were measured using fluorescent 
microscopy every second day in the avascular tail fin area of the embryo.  Confocal 
microscopy was used to visualize the invading tumor cells (labeled in red), against the 
Fli:GFP background of the zebrafish embryo which labels blood vasculature (green).  
Individual cell invasion can be detected in this model (He et al submitted). Over 5 days, a 
marked increase of invasion was visible upon ectopic expression of wild type USP4, but 
not its inactive CS mutant (Fig. 3e, f).  Treatment with SB431542, a selective TβRІ 
kinase inhibitor, reduced the invasion and micrometastasis of all samples (Fig.3f and 3g).  
At the end of the 5 days, wild-type USP4 infection in MCF10A-Ras cells resulted in 55% 
of zebrafish embryos displaying invasion, whilst the USP4 cs mutant and control samples 
showed invasion in 35% and 36% embryos, respectively (p<0.01) (Fig. 3f and 3g).  Due 
to the transparent nature of the zebrafish embryo, invading cells were also visible with 
light microscopy (Fig.3h).     
MDA-MB-231 is a highly aggressive human breast cancer cell line, and 
metastasis of these cells in a mouse and zebrafish embryo xenograft model were found to 
be dependent on TGF-β receptor signaling in tumor cells 26, 27 (Drabsch and ten Dijke, 
unpublished results) . In vitro qPCR analysis indicated that endogenous USP4 is required 
for efficient induction of metastasis-related TGF-β target genes, such as IL-11, CTGF, 
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CXCR4, PTHrP and MMPs (Fig. 3i). Similar results were obtained with other shUSP4 
lentivirus (data not shown). 
Subsequently, invasion and metastasis properties of USP4 depleted MDA-MB-
231 cells were analyzed in zebrafish embryos. MDA-MB-231 cells with stable depletion 
of endogenous USP4 were injected into the ducts of Cuvier 48 hpf.  The zebrafish 
embryos were analyzed over 5 dpi (see representative images of the tail fin area in Fig. 
3j).  The control cells showed 62% of zebrafish embryos with invasion, whereas 
knockdown of USP4 by 3 independent shRNAs attenuated the invasion (Fig. 3k).  
Furthermore, the amount of micrometastasis was also reduced upon USP4 depletion 
(Fig.3l). Taken together, these results suggest that USP4 stimulates TGF-β-induced 
breast cancer invasion and metastasis. 
When we analyzed the subcellular distribution of endogenous USP4, we found it 
to be mainly present in nucleus. This prompted us to investigate how USP4 could 
maintain cell surface TβRІ levels at the plasmamembrane. Sequence analysis revealed 
that USP4 contains an Akt consensus RxRxxS/T phosphorylation motif 6 at Ser 445. The 
motif is also conserved in USP4 orthologues (Fig 4a). It has been shown that for certain 
Akt substrates, phosphorylation triggers their nuclear export 28. We therefore reasoned 
that USP4 is a substrate of Akt, whose phosphorylation may influence USP4 subcellular 
localization.  Consistent with the hypothesis, we found that an activated allele of Akt 
(myr-Akt1) interacts with USP4 in transfected cells (Fig. 4b). In addition, USP4 was 
found to associate with Akt endogenously (Fig. 4c). To examine whether USP4 is a 
substrate for Akt, we used a phospho-specific antibody that recognizes the optimal Akt 
consensus phosphorylation motif (p-Ark substrate). We found that expression of 
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activated Akt significantly enhanced the phosphorylation of wild-type USP4, whereas 
USP4-S445A phosphorylation was not detected by p-Artk substrate antibody (Fig. 4b and 
4d). The reactivity of USP4 with this antibody was reversed when the cell lysates were 
incubated with lambda phosphatase (Fig. 4e). Moreover, insulin growth factor (IGF)-1 or 
TGF-β-induced endogenous USP4 phosphorylation as detected by the Akt substrate 
antibody. Notably, the phosphorylation of USP4 was decreased in cells that were treated 
with LY294002, a selective inhibitor for phosphatidylinositol 3-kinase (PI3K) (Fig. 4f).  
To investigate the effect of Akt on USP4 subcelluar localization we used HeLa 
cells stably expressing wild type USP4 or USP4 S44A/S445D mutants and confocal 
analysis. While USP4 S445A mutant was almost exclusively present in the nuclei, the 
USP4 S445D showed a significant increase in cytoplasmic localization when compared 
with wild-type USP4 (Fig. 4g).  Importantly, LY294002 treatment reduced the 
cytoplasmic signal of endogenous USP4 (Fig. 4h). To validate these findings, we 
examined the effect of activated myr-Akt on the localization of wild type USP4 or 
S44A/S44D USP4 mutants using immunofluorescence microscopy and cellular 
fractionation. We observed that the expression of activated myr-Akt promoted the 
cytoplasmic and membrane localization of wild-type USP4 (Fig 4i and 4j). In contrast, in 
the presence of activated Akt the non-phosphorylatable S445A USP4 mutant was still 
restricted to the nuclear compartment (Fig 4i and 4j). Conversely, a significant fraction of 
the phospho-mimetic USP4 S445D mutant was located in the cytoplasm, and its 
localization was not much affected by the expression of activated Akt (Fig 4i and data not 
shown). Futhermore, endogenous USP4 located in membrane and cytoplasm became 
completely nuclear or increased in membrane/cytoplasm localization upon LY294002 
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treatment and activated Akt expression, respectively (Fig. 4k). These results together 
indicate that Akt-induced USP4 phosphorylation affects its subcelluar distribution by 
promoting more USP4 to be present in membrane and cyoplasm. 
USP4 is a stable protein as it can deubiquitylate itself 29; Consistent with this, 
wild type USP4 was found to be more stable than USP4 CS mutant (data not shown). 
Time-course experiments in cells subjected to treatment with protein synthesis inhibitor 
cycloheximide (CHX) in the absence or presence of LY294002 or ectopically expressed 
activated Akt revealed that USP4 halflife was shortened and prolonged, respectively (Fig 
5a). Consistent with these results we found that the S445A mutant was degraded more 
rapidly than wild-type USP4 and S445D mutant (Fig. 5b). Compared with wild-type 
USP4, S445A mutant demonstrated an increased level of conjugation with polyubiquitin 
chains (Fig. 5c), suggesting that the impaired protein halflife of the S445A mutant is due 
to its elevated ubiquitination. We found that USP4 formed complex with itself and also 
interacted with USP15, USP19 and USP11, the other DUBs that were identified in our 
genetic screen (Fig. S3a). Mutation of the Akt phosphorylation site on USP4 (S445A 
mutant) mitigated the ability to associate with itself or other USPs (Fig. 5d and 5e, 
Supplementary Fig. S3b). Particularly, when USP4 was coexpressed with USP15, we 
observed an elevation in USP4 expression (Supplementary Fig. S3a). An enforced long 
stability of USP4 protein was detected when it was co-expressed with USP15 (Fig. 5f). 
These data suggest that Akt mediated phosphorylation on Ser 445 is required for USP4 to 
form homomeric complexes and heteromeric complexes with other DUBs, particularly 
with USP15. As USP4 binding partners, USP15, USP19 and USP11 were also observed 
to deubiquitinate TβRІ when they were overexpressed (Fig.S3c). We focused on USP15 
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and found it could also serve as a deubiquitylase for TβRІ (Supplementary Fig. S3d) but 
that this relied on endogenous USP4 (Supplementary Fig. S3e).  
Consistent with the notion that wild-type USP4 and USP4 S445D mutant are 
more located at plasmamembran and stable than USP4 S445A mutant, we found that 
S445A mutant had lost the ability to remove polyubiquitin chains from TβRІ (Fig. 5g). 
This suggests that Akt mediated USP4 phosphorylation is required for USP4 to serve as a 
deubiquitylase for TβRІ. To further investigate the functional cooperation between 
PI3K/Akt and TGF-β/TβRI signaling pathways via USP4, we examined the effect of 
USP4 depletion or TβRІ kinase inhibitor on IGF-1- or activated myr-Akt-induced 
migration of MDA-MB -231 cells. We found that both treatments could partially reduce 
IGF-1/Myr-Akt-induced cell migration (Fig. 5h and 5i).  Our current study suggest a 
working model in which in invasive/metastatic breast cancer cells, Akt activated by 
growth factors/TGF-β induces phosphorylation of USP4, which associates with TβRI in 
the membrane to stabilize it, and then enforces the TGF-β receptor-induced pro-
migratory/invasive and metastatic responses in breast cancer cells (Fig. 5j). Akt has been 
shown to reduce Smad3 function in Hep3B cells in which TGF-β induces an apoptotic 
response 30, 31. Akt can directly associate with unphosphorylated Smad3 and sequester it 
outside the nucleus. However, Smad3 levels are often reduced in advanced human tumors 
with low levels being sufficient for tumor promotion32, 33. Activation of Akt may redirect 
TGF-β signaling and thereby contribute to its switch from tumor suppressor to tumor 
promoter. With DUBs being druggable targets34, it would be interesting to develop 
inhibitors for USP4 and test their potential for anti-invasive and anti-metastatic properties. 
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METHODS 
Cell culture and reagents. MEFs from wild-type and USP4-/- mice were kindly provided 
by Xiongbin Lu (University of Texas MD Anderson Cancer Center, Houston, TX, 
USA)35. HEK293T cells, HeLa cervical cancer cells, MDA-MB-231breast cancer cells 
and MEFs were cultured in Dulbecco’s modified Eagle’s (DMEM) with 10% FBS and 
100 U/ml penicillin/streptomycin. Myc-USP4 wt and Myc-USP4 C311S expression 
constructs were cloned and verified by DNA sequencing. USP4 wt and C311S mutant 
were subcloned into pLV bc puro lenti virus construct.  USP4 S445A and USP4 S445D 
were made by side directed mutation and confirmed by sequencing. Myr-Akt constructs 
were kindly provided by Dr. Paul Coffer. MG132 were purchased from Sigma; IGF-
1(R&D 291-G1), LY294002 (Cell signaling), λ-phosphatase (Biolabs). The antibodies 
used for immunoprecipitation, immunoblotting and immunofluorescence were raised 
against the following proteins: β-actin (A5441, Sigma), c-Myc (a-14, sc-789, Santa Cruz 
biotechnology), HA (Y-11, sc-805, Santa Cruz biotechnology), HA (12CA5),  Flag (M2, 
Sigma), USP4 (U0635, Sigma), TβRІ (V22, Santa Cruz), Akt (#2938 Cell signaling),  
phosphor-Akt substrate (RXRXXS*/T*) (#10001, Cell Signaling), phosphor-Akt 
(Ser473) (#9271, Cell Signaling), V5 (Invitrogen), USP15 (BETHYL), USP11 
(BETHYL A301-613A), USP19 (BETHYL A301-586A), N-cadherin(610920 BD), 
Tubulin (#2146 Cell signaling), HDAC3 (#3949 Cell signaling), Smad4 (B8 Santa Cruz), 
Smad2/3 (610842 BD), phospho-Smad2 (#3101 Cell signaling), Lys48-polyUb (#8081 
Cell signaling), Ub (P4D1 Santa Cruz), Fibronectin (Sigma), SMA(Sigma), vimentin 
(#5741 Cell signaling), E-cadherin (BD 610181), HA (12CA5).  
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Lentiviral transduction and generation of stable cell lines. Lentiviruses were produced 
by transfecting shRNA targeting plasmids together with helper plasmids pCMV-VSVG, 
pMDLg-RRE (gag/pol), and pRSV-REV into HEK293T cells. Cell supernatants were 
harvested 48 h after transfection and were either used to infect cells or stored at -80 °C.  
To obtain stable cell lines, cells were infected at low confluence (20%) for 24 h with 
lentiviral supernatants diluted 1:1 with normal culture medium in the presence of 5 ng/ml 
of polybrene (Sigma). 48 h after infection, cells were placed under puromycin selection 
for one week, and then passaged before use. Puromycin was used at 1 µg/ml to maintain 
MDA-MB-231 cells. Lentiviral shRNAs were obtained from Sigma (MISSION® 
shRNA). Typically, 5 shRNAs were identified, tested, and the most effective two 
shRNAs were used for the experiment. We used TRCN0000004040 (#1), 
TRCN0000004041 (#2) and TRCN0000004042 (#3) for human USP4 knockdown. 
 
Transcription reporter assay.  HEK293T cells were seeded in a 24-well plate and 
transfected with the indicated plasmids using calcium phosphate. 24 h after transfection, 
cells were treated with TGF-β3 (5 ng/ml) overnight or left untreated and then harvested. 
Luciferase activity was measured with a Perkin Elmer luminometer. The internal 
transfection control, β-gal (30 ng), was used to normalize luciferase activity. Each 
experiment was performed in triplicate and the data represent the mean ± SD of three 
independent experiments.  
 
Immunoprecipitation, immunoblotting and biotinylation. Cells were lysed with 1 ml 
lysis buffer (20 mM Tris-HCl pH 7.4, 2 mM EDTA, 25 mM NaF, and 1% Triton X-100) 
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plus protease inhibitors (Sigma) for 10 min at 4°C. After centrifugation at 12 x 103 ×g for 
15 min, the protein concentration was measured and equal amounts of lysate used for 
immunoprecipitation. Immunoprecipitation was performed with different antibodies and 
protein A-sepharose (GE Healthcare Bio-Sciences AB) for 3 h at 4°C. Thereafter, the 
precipitants were washed three times with washing buffer (50 mM Tris-HCl pH 8.0, 150 
mM NaCl, 1% Nonidet P-40, 0.5% sodium deoxycholate, and 0.1% SDS) and the 
immune complexes eluted with sample buffer containing 1% SDS for 5 min at 95°C. The 
immunoprecipitated proteins were then separated by SDS-PAGE. Western blotting was 
performed with specific antibodies and secondary anti-mouse or anti-rabbit antibodies 
conjugated to horseradish peroxidase (Amersham Biosciences). Visualization was 
achieved with chemiluminescence. For proteins that close to IgG heavy chain, for 
instance TβRІ blottings, protein A-HRP was used. For biotinylation analysis of cell 
surface receptors, the cells were biotinylated for 40 min at 4oC and then incubated at 
37oC for indicated times. The biotinylated cell surface receptors were precipitated with 
strepavidin beads and analyzed by immunoblotting. 
 
Immunofluorescence. Cells were fixed for 10 min in 4% paraformaldehyde in phosphate 
buffered saline (PBS), permeabilized with 0.2% TritonX100-PBS, and then blocked with 
3% bovine serum albumin (BSA) in PBS for 30 min at room temperature. Specific first 
antibodies were diluted in 3% BSA-PBS and incubated with the slides for 3 h at room 
temperature. Secondary AlexaFluor488-labeled anti-mouse antibody (Molecular Probes) 
or AlexaFluor593-labeled anti-rabbit antibody (Molecular Probes) were added at a 
dilution of 1:200 in 3% BSA-PBS and incubated for 1 h at room temperature. Coverslips 
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were mounted with VECTASHIELD mounting medium (Vector Laboratories, Inc.). 
Fluorescence images were acquired with a Zeiss Axioplan microscope. 
 
Ubiquitination assay. Cells were washed with PBS and lysed in two pellet volumes of 
RIPA buffer (20 mM NAP pH 7.4, 150 mM NaCl, 1% Triton, 0.5% sodium-deoxycholate, 
and 1% SDS ) supplemented with protease inhibitors and 10 mM N-ethylmaleimide 
(NEM). Lysates were sonicated, boiled at 95°C for 5 min, diluted with RIPA buffer 
containing 0.1% SDS, then centrifuged at 4°C (16 x 103 x g for 15 min). The supernatant 
was incubated with specific antibody and protein A-sepharose for 3 h at 4°C. After 
extensive washing, bound proteins were eluted with 2 x SDS sample buffer and separated 
by SDS-PAGE, followed by immunoblotting. 
 
Nickel pull down assay. Cells were lysed in 6M guanidine-HCl, 0.1 M 
Na2HPO4/NaH2PO4, and 10 mM imidazole, followed by nickel bead purification and 
immunoblot analysis. 
 
Real-time RT-PCR (qRT-PCR). Total RNAs were prepared using NucleoSpin® RNA 
II kit (BIOKÉ, Netherlands). 1 μg RNA was reverse-transcribed using the RevertAid™ 
First Strand cDNA Synthesis Kits (Fermentas). Real-time PCR was conducted with 
SYBR Green incorporation (Applied Bioscience) using a StepOne Plus real-time PCR 
system (Applied Bioscience). All of the values of the target gene expression level were 
normalized to GAPDH. All Primers used for qRT-PCR are listed as follows:  
CTGF forward, 5'-TGCGAAGCTGACCTGGAAGAGAA-3' 
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CTGF reverse, 5'-AGCTCGGTATGTCTTCATGCTGGT-3' 
IL-11 forward, 5'-ACTGCTGCTGCTGAAGACTC-3' 
IL-11 reverse, 5'-CCACCCCTGCTCCTGAAATA-3' 
CXCR4 forward, 5'-CAGTGGCCGACCTCCTCTT-3' 
CXCR4 reverse, 5'-CAGTTTGCCACGGCATCA-3' 
PTHrP forward, 5'-TTCTTCCCAGGTGTCTTGAG-3' 
PTHrP reverse, 5'-TTTACGGCGACGATTCTTCC-3' 
MMP2 forward, 5'-TGCCTGGAATGCCAT-3' 
MMP2 reverse, 5'-GTTCTCCAGCTTCAGGTAAT-3' 
MMP9 forward, 5'-TACTGTGCCTTTGAGTCCG-3' 
MMP9 reverse, 5'-TTGTCGGCGATAAGGAAG-3' 
GAPDH forward, 5'-CCATCCACAGTCTTCTGGGT-3' 
GAPDH reverse, 5'-GATCATCAGCAATGCCTCCT-3' 
mCxcr4 forward, 5'-TTACCCCGATAGCCTGTGGAT-3' 
mCxcr4 reverse, 5'-GCAGGACGAGACCCACCAT-3' 
mSmad7 forward, 5'-TGGATGGCGTGTGGGTTTA-3' 
mSmad7 reverse, 5'-TGGCGGACTTGATGAAGATG-3' 
mSnoN forward, 5'-AAGCAAGCGTGATTCAGAAGATT-3' 
mSnoN reverse, 5'-CCCCTTGTCGTCTTCACCAT-3' 
mCTGF reverse, 5'-GGCCTCTTCTGCGATTTCG-3' 
mCTGF forward, 5'-CCATCTTTGGCAGTGCACACT-3' 
mPAI-1 forward, 5’- GCCAACAAGAGCCAATCACA-3’ 
mPAI-1 reverse, 5’- AGGCAAGCAAGGGCTGAAG-3’ 
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mGAPDH forward, 5'-AACTTTGGCATTGTGGAAGG-3' 
mGAPDH reverse, 5'-ACACATTGGGGGTAGGAACA-3' 
 
Zebrafish embryo assay. Zebrafish (Danio rerio), AB strain, were kept at 28.5°C under 
a light and dark cycle of 14 and 10 hours, respectively. Fish staging and embryo 
production were carried out as described previously36, 37. Capped mRNAs were 
synthesized using T7 Cap Scribe (Roche) according to the manufacturer’s instructions. 
For preparation of digoxigenin labeled antisense probe, plasmid containing the usp4 
cDNAs was linearized with KpnI. Linearized template DNA was transcribed in vitro with 
T7 polymerase using the digoxigenin-UTP (Roche). In situ hybridizations were 
performed as previously described38. Embryo stages are given in Hours Post Fertilization 
at standard temperature (hpf).  
To knockdown usp4 gene function, morpholino oligonucleotides were 
synthesized by Gene Tools company (zusp4-MO: 5’-
AGCGAGTGAACCCGCAGTGACCGCG-3’). Control MO sequence is 5'-
GCGCCATTGCTTTGCAAGAATTG-3'. All of oligos were dissolved in nuclease-free 
water to make a 24 μg/μl storage concentration. The mRNAs and morpholino 
oligonucleotides were injected into yolk of fertilized eggs at single-cell stage. All the 
embryo injections were carefully controlled with the same amount of control MO and 
control GFP mRNA. 
Total RNA was isolated from embryos at different stages using Trizol reagent 
(TAKARA). The first strand cDNAs synthesized from total RNAs were used as 
templates following the SuperScript Kit (Invitrogen). qRT-PCR reactions were performed 
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for 30 cycles and a final extension for 6 min with internal β-actin control. Primers used 
are list as follows:  
ntl forward, 5’-ACCCTATACACCCCCACCTC-3’ 
ntl reverse, 5’-ATAATAGGCACCGCTCATGC-3’ 
gsc forward, 5’-GACGAGCAGCTGGAGGCACTGGA-3’ 
gsc reverse, 5’-TCAGCTGTCAGAATCCACGTCGCT-3’ 
sox32 forward: 5’-ACCTTGAAATGAGACACACC-3’ 
sox32 reverse: 5’-TGAAGGCATCTTGCTGCTCC-3’ 
sox17 forward: 5’-CATGATGCCTGGCATGGGGC-3’ 
sox17 reverse: 5’-CACTCATACCTTCCGTGCAC-3’ 
 
Migration and Invasion Assays. Transwell assay were performed in 24-well PET inserts 
(Falcon 8.0 µm pore size) for migration assays. MDA-MB231 stable cells were serum 
starved overnight. Then, 50 x 103 or 10 x 103 cells were plated in transwell inserts (at 
least 3 replicas for each sample) and left treated with or without SB431542 (5 μM) for 8 
hr. Cells in the upper part of the transwells were removed with a cotton swab; migrated 
cells were fixed in PFA 4% and stained with crystal Violet 0.5%. Filters were 
photographed and the total number of cells counted. Every experiment was repeated at 
least three times independently. 
 
Zebrafish embryonic invasion and metastasis assay. We used a zebrafish embryo 
xenograft model developed by Snaar-Jagalska and collegues (in submission), where 
mammalian tumour cells are injected into the zebrafish embryonic blood 
N
at
ur
e 
Pr
ec
ed
in
gs
 : 
hd
l:1
01
01
/n
pr
e.
20
12
.6
80
4.
1 
: P
os
te
d 
19
 J
an
 2
01
2
 19
circulation.  Approximately 400 tumor cells labeled with a red fluorescent cell tracer 
were injected into the blood of 48 hours post fertilization (hpf) Fli-Casper zebrafish 
embryos at the ducts of Cuvier39 (Fig. 3d).  After injection, some of the tumour cells 
disseminate into the embryo blood circulation whilst the rest remain in the 
yolk.  Zebrafish embryos are maintained for 5 days post injection (dpi) at 33˚C, a 
compromise for both the fish and cell lines40. The tumor cells that enter into the blood 
stream preferentially invade and micrometastasise into the posterior tail fin area (Fig. 
3e).  Invasion is can be visualized as a single cell which has left the blood vessel which 
can subsequently form a micrometastasis (3~50 cells).  Pictures were taken by confocal 
microscopy at 1, 3 and 5 dpi and the percentage of invasion and micrometastasis were 
counted. Every experiment was repeated at least two times independently. 
 
Cellular fractions. Cytosolic, membrane and nuclear fractions were prepared using the 
ProteoExtract kit (Calbiochem) according to the manufacturer’s instructions. 
 
Statistical analysis. Statistical analyses were performed with a two-tailed unpaired t-test. 
P < 0.05 was considered statistically significant. 
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FIGURE LEGENDS 
 
 
Figure 1 USP4 is a DUB required for TGF-β signaling. (a) Diagram of genome-wide 
cDNA screening data in HEK293T cells in which USPs that activate TGF-β-induced 
Smad3/Smad4-dependent CAGA12-Luc transcriptional reporter are indicated. The X and 
Y-axes are the relative luciferase activity in two replicates, p<0.01.(b,c) Effect of USP4 
wild-type (USP4WT) and USP4 deubiquitin enzyme activity inactive mutant (USP4 
C311S)  (b) or knockdown (shUSP4 #1 and #2 ) (c) on CAGA12-Luc transcriptional 
response induced by TGF-β (5 ng/ml) in HEK293T cells. Data are presented as mean ± 
SD. Co.vec, empty vector; Co.sh, non-targeting shRNA. (d, e) Immunoprecipitation (IP) 
and immunoblotting (IB) analysis of Smad2/Smad4 complex formation in MCF10A-Ras 
breast epithelial cells over-expressing USP4 wt /USP4 cs mutant (d) or knocking down 
USP4 by shRNA (shUSP4 #1 and #2) (e) and stimulated with TGF-β (5 ng/ml) for 
indicated time point. (f) Kinetics of TGF-β (5 ng/ml)-induced Smad2 phosphorylation in 
wild type MEFs (USP4+/+) and USP4 knock-out MEFs (USP4-/-). Cell lysates were 
immunoblotted for phosphorylated Smad2 (p-Smad2) and total Smad2.  (g) qRT-PCR 
analysis of TGF-β target genes Smad7, SnoN, CTGF and PAI-1 in USP4+/+ and USP4-/- 
MEFs treated with TGF-β (5 ng/ml) for indicated time points. Values and error bars 
represent the mean ± SD of triplicates and are representative of at least two independent 
experiments. (h) The expression patterns of no tail (ntl) and goosecoid (gsc) under 
conditions that caused usp4 over-expression (usp4 mRNA, 100 ng) and knock-down (usp4 
MO, 0.5 ng). All embryos are shown in the 70% epiboly stage. All the embryo injections 
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were carefully controlled with the same amount of control MO and control GFP mRNA. 
(i) qRT-PCR analysis of zebrafish embryos with usp4 over-expression (usp4 mRNA) or 
knock-down (usp4 MO). Values and error bars represent the mean ± SD of triplicates and 
are representative of at least two independent experiments. 
 
Figure 2 USP4 interacts with and deubiquitinates TβRI. (a) Endogenous TGF-β 
receptors of MDA-MB-231 cells were covalently affinity labeled with 125I-labeled TGF-β 
ligand, cell lysates were then harvested for immunoprecipitation (IP) with TβRI, non-
specific (ns), USP4 or USP15 antibodies as indicated. Endogenous TβRI and TβRII that 
were immunoprecipitated by antibodies were detected by autoradiography. (b) TGF-β 
treatment increased the endogenous interaction between USP4 and TβRI as demonstrated 
by IP and immunoblotting (IB) analysis of MDA-MB-231 cells treated with TGF- β (5 
ng/ml) for 4 h. Input and IP with non-specific (ns) and TβRI antibody are shown. (c) Left 
panel: IB analysis of whole cell lysate (TCL) and immunoprecipitates derived from 
HEK293T cells transfected with HA-Ub, TβRI-Flag and Myc-USP4 wt/cs and treated 
with or without MG132 for 2h as indicated. Right panel: the same sample from left panel 
was blotted with anti-Lys48-polyUb antibody. (d) HA-Ub-expressed HEK293T cells 
were transfected with Myc-USP4 wt/cs and treated with TGF-β (5 ng/ml) for 2 h as 
indicated. Cells were then harvested for IP with anti-TβRI antibody followed with IB 
analysis. (e) HA-Ub expressed HEK293T cells were infected with control (co.) and two 
independent lentivirus-mediated USP4 shRNA (#1 and #2) and treated with TGF-β (5 
ng/ml) for 2 h as indicated. Left panel: cells were harvested for IP with TβRI antibody 
followed with IB analysis. Right panel: the sample from the left panel was blotted with 
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anti-Lys48-polyUb antibody. (f) Biotinylation analysis of cell surface receptors. COS7 
cells transfected with caTβRI-Flag along with or without USP4 wild-type (wt)/c311s (cs) 
were biotinylated for 40 min at 4oC and then incubated at 37oC for various times. The 
biotinylated cell surface receptors were precipitated with strteptavidin beads and analyzed 
by anti-Flag immunoblotting. Lower right panel: quantification of the band intensities in 
upper panel. Band intensity was normalized to the t=0 controls. Results are shown as 
mean ± SD of three independent sets of experiments. (g) MDA-MB-231 cells infected 
with control (Co.shRNA) or USP4 shRNA lentivirus (#1) were biotinylated for 40 min at 
4oC and then incubated at 37oC with TGF-β (5 ng/ml) for indicated times to stimulate 
receptor internalization and treated with TGF-β (5 ng/ml) for different time point as 
indicated. The biotinylated cell surface receptors were precipitated with strteptavidin 
beads and analyzed by anti-TβRІ immunoblotting.  5% whole cell lysates were loaded as 
input showing P-Smad2 and USP4 levels. Actin was included as a loading control. (h) 
Expression levels of TβRI were analysed by IB in USP4+/+ and USP4-/-  MEFs treated 
with cyclohexamide (CHX, 20 μg/ml) for the indicated time. IB for Actin was included 
as reference.  
 
Figure 3 USP4 increases TGF-β-induced EMT, invasion and metastasis. (a) Control and  
USP4 stably-depleted (with shRNA #1 or #2) MCF10A-Ras cells were treated with TGF-
β for 36 h and then lysed for IB analysis for changes in expression of  EMT marker 
proteins, i.e. N-cadherin, fibronectin, smooth muscle actin (SMA), vimentin and E-
cadherin. (b) Control and USP4 wild-type (wt)/c311s (cs) stably expressed MCF10A-Ras 
cells were treated with TGF-β (5 ng/ml) and SB431542 (5 μM) for 36 h as indicated. 
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Cells were then harvested for IB analysis of EMT marker proteins. (c) USP4 stably-
depleted MDA-MB-231 cells (#1 and #2) were plated for cell migration assays (see 
Methods). Cells were treated with TGF-β (5 ng/ml) for 8 h. Migrated cells were counted 
from four random fields, and mean±SD were calculated (P<0.05). Representative results 
are shown on the left panel. (d) Diagram of zebrafish embryonic experimental metastasis 
model (Methods). (e) MCF10A-Ras (M2) cells stably expressing control vector 
(Co.vector), USP4 WT or USP4 C311S were injected into the blood circulation of the 2 
dpf zebrafish embryos.  Cells were treated with or without SB431542 (10 μM) for 24 h 
prior to injection, and SB431542 (5 μM) was added to zebrafish environment.  Pictures 
were taken by confocal microscopy and representative images of zebrafish at 5 days post 
injection (dpi) are shown. (f) Percentage of embryos displaying invasion are shown at the 
1, 3 and 5 dpi.  (g) The final percentage of zebrafish embryos displaying invasion and 
experimental metastasis at 5 dpi.  The results are shown as mean ± SD of two 
independent experiments. Control without SB431542 n= 144, USP4 WT without 
SB431542 n= 152, USP4 C311S without SB431542 n= 153, Control with SB431542 n = 
152, USP4 WT with SB431542 n = 152 and USP4 C311S with SB431542 n = 153.  (h) 
Representative light microscopy image of posterior tail of a control zebrafish embryo 
(upper panel) and 5 dpi zebrafish embryo displaying invasion and micrometastasis of 
MCF10A-Ras cells (lower panel). Red arrow indicate metastatic cells. (i)  qRT-PCR 
analysis of TGF-β target and invasion-related genes IL-11, CXCR4, CTGF, PTHrP, 
MMP2 and MMP9 in MDA-MB-231 breast cancer cells infected with non-targeting 
shRNA or USP4 shRNA (#1) and treated with TGF-β (5 ng/ml) for indicated time point. 
Co.sh, non-targeting shRNA; shUSP4, USP4 shRNA. Values and error bars represent the 
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mean ± SD of triplicates and are representative of at least two independent experiments. 
(j-l) MDA-MB-231 cells stably infected with empty vector (Co.shRNA) or 3 independent 
shRNAs (#1, #2 and #3) targeting USP4 were injected into the blood circulation of 48 hpf 
zebrafish. Pictures were taken by confocal microscopy and representative images of 
zebrafish at 5 dpi are shown (j). Invasion (k) and experimental micrometastasis (l) were 
detected in the posterior tail fin over 5 days. The final percentage of zebrafish embryos 
displaying invasion and metastasis at 5 dpi. The results are shown as mean ± SD of two 
independent experiments (p<0.05). The results are shown as mean ± SD of two 
independent experiments. Control n= 175, shUSP4 #1 n= 172, shUSP4 #2 n=173, and 
shUSP4 #3 n= 165.   
 
Figure 4 Akt phosphorylates USP4 and promotes its membrane and cytoplasmic 
localization. (a) Sequence alignment of Akt phosphorylation site within USP4 
orthologues of different species and known Akt phosphorylating protein p27, p21 and 
Skp2. (b) Akt interacts with and phosphorylates USP4. HEK293T cells were transfected 
with indicated plasmids and harvest for Co-immunoprecipitation (IP) and immunoblot 
(IB) analysis. (c) Endogenous interaction between USP4 and Akt detected in HeLa cells. 
Cell lysates were IP with USP4 antibody followed by IB with Akt antibody. (d) IB 
analysis of whole cell lysate (TCL) and immunoprecipitates derived from HEK293T cells 
transfected with Flag-USP4 WT, Flag-USP4 S445A and/or HA-Myr-Akt plasmids. (e) IP 
and IB analysis of HEK293T cells transfected with Flag-USP4 WT, Flag-USP4 S445A 
and/or HA-Myr-Akt and preincubated with or without λ-phosphatase as indicated. (f) IB 
analysis of whole cell lysate (TCL) and immunoprecipitates derived from serum starved 
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HeLa cells treated with IGF-1 (200 ng/ml), TGF-β (5 ng/ml) and LY294002 (50 μM) for 
8 h as indicated. (g) Immunofluorescence and 4, 6-diamidino-2-phenylindole (DAPI) 
staining of HeLa cells stably transfected with USP4 WT, S445A or S445D plasmids. 
Scale bar, 20 μm. (h) Immunofluorescence and DAPI staining of HeLa cells treated with 
control DMSO or LY294002 (50 μM) for 8 h. Scale bar 20 μm. (i) Immunofluorescence 
and DAPI staining of HeLa cells transfected with HA-Myr-Akt along with USP4 WT, 
USP4 S445A or USP4 S445D. Scale bar, 20 μm. (j) HeLa cells transfected with USP4 
WT, USP4 S445A and HA-Myr-Akt as indicated were harvested for membrane, 
cytoplasm and nuclear extraction and followed by IB analysis. (k) HeLa cells were 
transfected with HA-Myr-Akt. 30 h after transfection, cells were treated with LY294002 
(50 μM) for 8 h as indicated. Cells were then harvested for membrane, cytoplasm and 
nuclear extraction and followed by IB analysis. For j,k, N-cadherin, Tubulin and HDAC3 
were analysed as membrane (mem), cytoplasm (cyto) and nuclear (nuc) fraction marker, 
respectively. 
 
Figure 5 Akt mediated phosphorylation affects USP4 stability and DUB activity towards 
TβRI (a) Immunoblotting (IB) analysis of HeLa cells transfected with empty vector 
(Co.vector) or Myr-Akt and treated with DMSO, LY294002 (50 μM)  and cyclohexamide 
(CHX, 20 μg/ml) as indicated. Actin was included as a loading control. (b)Left panel: IB 
analysis of HEK293T cells transfected with USP4 S445D/ USP4 S445A /USP4 WT and 
treated with CHX (20 μg/ml) for indicated time point. Right panel: quantification of the 
band intensities in left panel. Band intensity was normalized to the t=0 controls. Results 
are shown as mean ± SD of three independent sets of experiments. (c) His-Ub stably 
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expressed HEK293T cells were transfected with Flag-USP4 WT or Flag-USP4 S445A 
mutant and harvested for Ni NTA pull down and IB analysis. (d,e) IB analysis of whole 
cell lysate (TCL) and immunoprecipitates derived from HEK293T cells transfected with 
Myc-USP4 (d) / V5-USP15 (e) along with Flag-USP4 WT/S445A (SA)/S445D (SD). (f) 
IB analysis of Myc-USP4-expressed HEK293T cells transfected with control empty 
vector (Co.vector) or USP15 and treated with CHX (20 μg/ml) for indicated time point. 
(g) IB analysis of whole cell lysate (TCL) and immunoprecipitates (IP) derived from HA-
Ub-expressed HEK293T cells transfected with Flag-USP4 WT/S445A (SA)/S445D (SD). 
(h) Control (Co.) and USP4 stably depleted MDA-MB231 cells were plated for cell 
migration assays. Cells were treated with or without SB431542 (10 μM) and IGF-1 for 8 
h. (i) Control (Co.) and USP4 stably-depleted MDA-MB-231 cells were infected with or 
without Myr-Akt and plated for cell migration assay. Cells were treated with or without 
SB431542 (10 μM) for 8 h. For h and i, migrated cells were counted from four random 
fields, and mean±SD were calculated (P<0.05). (j) Working model for TGF-β signaling 
regulation: Akt phosphorylating USP4 serves as deubiquitinating enzyme for TβRІ. 
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